Display options
Cite
He X, Yuan Z, Gaeke S, et al. Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS Appl Bio Mater. 2021;4(2):1461-1469doi: 10.1021/acsabm.0c01334.
He, X., Yuan, Z., Gaeke, S., Kao, W. W., Li, S. K., Miller, D., Williams, B., & Park, Y. C. (2021). Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS applied bio materials, 4(2), 1461-1469. https://doi.org/10.1021/acsabm.0c01334
He, Xingyu, et al. "Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye." ACS applied bio materials vol. 4,2 (2021): 1461-1469. doi: https://doi.org/10.1021/acsabm.0c01334
He X, Yuan Z, Gaeke S, Kao WW, Li SK, Miller D, Williams B, Park YC. Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS Appl Bio Mater. 2021 Feb 15;4(2):1461-1469. doi: 10.1021/acsabm.0c01334. Epub 2021 Jan 22. PMID: 35014495.
Copy Download .nbib Format: NLM
Share it on

ACS Appl Bio Mater. 2021 Feb 15;4(2):1461-1469. doi: 10.1021/acsabm.0c01334. Epub 2021 Jan 22.

Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye.

ACS applied bio materials

Xingyu He, Zheng Yuan, Samantha Gaeke, Winston W-Y Kao, S Kevin Li, Daniel Miller, Basil Williams, Yoonjee C Park

Affiliations

  1. Department of Chemical & Environment Engineering, College of Engineering and Applied Science, University of Cincinnati, 2901 Woodside Drive, Cincinnati, Ohio 45221, United States.
  2. Department of Ophthalmology, College of Medicine, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, Ohio 45267, United States.
  3. College of Pharmacy, University of Cincinnati, 3255 Eden Avenue, Cincinnati, Ohio 45229, United States.
  4. Cincinnati Eye Institute, 1945 CEI Drive, Cincinnati, Ohio 45242, United States.
  5. Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, United States.

PMID: 35014495 DOI: 10.1021/acsabm.0c01334

Abstract

To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may lead to local side effects. The present study attempts to develop a dosage-controllable drug delivery implant that consists of a nanoporous biodegradable PLGA capsule and light-activated liposomes. Controllable drug release from the implant was achieved using a pulsed near-infrared (NIR) laser both in vitro and in vivo. The in vitro drug release kinetics from two different initial dose implants, 1000 and 500 μg, was analyzed by fitting zero-order and first-order kinetics, as well as the Korsmeyer-Peppas and Higuchi models. The 1000 and 500 μg implants fit the first-order and zero-order kinetics model, respectively, the best. The multiple drug releases in the vitreous were determined by an in vivo fluorimeter, which was consistent with the in vitro data. The dose released was also clinically relevant. Histology and optical and ultrasound imaging data showed no abnormality in the eyes received implant treatment, suggesting that the drug delivery system was safe to the retina. This on-demand dose-controllable drug delivery system could be potentially used for long-term posterior eye disease treatment to avoid frequent invasive injections.

Keywords: dose-controllable implant; drug delivery; laser-triggered drug delivery; long-term drug delivery; multiple releases; posterior eye diseases; triggered drug release

Publication Types